Literature DB >> 28854808

Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease.

Aaron Liew1,2,3, Giacomo Failla1,4, Giulia Molinari1,5, Manlio Prior1,6, Beniamino Zalunardo1,7, Daniela Pergolini1,8, Katja Knavs1,9, Matija Kozak1,9, Adriano Cortelazzo1,10, Patrick Van Dreden1,11, Ismail Elalamy1,12,13, Mariella Catalano1,10, Grigoris T Gerotziafas1,12,13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28854808      PMCID： PMC6714643          DOI： 10.1177/1076029617699086

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN： 1076-0296            Impact factor:   2.389


× No keyword cloud information.
  5 in total

1.  Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.

Authors:  Fariborz Mobarrez; Shu He; Anders Bröijersen; Björn Wiklund; Aleksandra Antovic; Jovan Antovic; Nils Egberg; Gun Jörneskog; Håkan Wallén
Journal:  Thromb Haemost       Date:  2011-05-26       Impact factor: 5.249

2.  Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.

Authors:  Thomas Gremmel; Renate Koppensteiner; Cihan Ay; Simon Panzer
Journal:  Eur J Clin Invest       Date:  2014-01-20       Impact factor: 4.686

3.  Statins decrease thrombin generation in patients with hypercholesterolemia.

Authors:  Armando Tripodi; Fabio Pellegatta; Veena Chantarangkul; Liliana Grigore; Katia Garlaschelli; Andrea Baragetti; Laura Lemma; Alberico Catapano
Journal:  Eur J Intern Med       Date:  2014-04-29       Impact factor: 4.487

4.  Critical limb ischemia: thrombogenic evaluation of two autologous cell therapy products and biologic profile in treated patients.

Authors:  Claire Tournois; Bernard Pignon; Marie-Antoinette Sevestre; Zoubir Djerada; Jean-Claude Capiod; Gaël Poitevin; Anne-Marie Delloup; Philippe Nguyen
Journal:  Transfusion       Date:  2015-07-29       Impact factor: 3.157

5.  Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

Authors:  Mourad Chaari; Ines Ayadi; Aurelie Rousseau; Eleftheria Lefkou; Patrick Van Dreden; Fatoumata Sidibe; Hela Ketatni; Vassiliki Galea; Amir Khaterchi; Racem Bouzguenda; Mounir Frikha; Lilia Ghorbal; Jamel Daoud; Choumous Kallel; Martin Quinn; Joseph Gligorov; Jean Pierre Lotz; Mohamed Hatmi; Ismail Elalamy; Grigoris T Gerotziafas
Journal:  BMC Cancer       Date:  2014-12-22       Impact factor: 4.430
  5 in total
  1 in total

1.  Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study.

Authors:  Grigoris T Gerotziafas; Theodoros Zografos; Ioannis Pantos; Eleftheria Lefkou; Audrey Carlo; Jawed Fareed; Patrick Van Dreden; Demosthenes Katritsis
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.